Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets

Brenda Waning; Margaret Kyle; Ellen Diedrichsen; Lyne Soucy; Jenny Hochstadt; Till Bärnighausen; Moon, Suerie
January 2010
Globalization & Health;2010, Vol. 6, p9
Academic Journal
Background: Universal access to antiretroviral therapy (ART) in low- and middle-income countries faces numerous challenges: increasing numbers of people needing ART, new guidelines recommending more expensive antiretroviral (ARV) medicines, limited financing, and few fixed-dose combination (FDC) products. Global initiatives aim to promote efficient global ARV markets, yet little is known about market dynamics and the impact of global policy interventions. Methods: We utilize several data sources, including 12,958 donor-funded, adult first-line ARV purchase transactions, to describe the market from 2002-2008. We examine relationships between market trends and: World Health Organization (WHO) HIV/AIDS treatment guidelines; WHO Prequalification Programme (WHO Prequal) and United States (US) Food and Drug Administration (FDA) approvals; and procurement policies of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM), US President's Emergency Plan for AIDS Relief (PEPFAR) and UNITAID. Results: WHO recommended 7, 4, 24, and 6 first-line regimens in 2002, 2003, 2006 and 2009 guidelines, respectively. 2009 guidelines replaced a stavudine-based regimen ($88/person/year) with more expensive zidovudine- ($154-260/ person/year) or tenofovir-based ($244-465/person/year) regimens. Purchase volumes for ARVs newly-recommended in 2006 (emtricitabine, tenofovir) increased >15-fold from 2006 to 2008. Twenty-four generic FDCs were quality-approved for older regimens but only four for newer regimens. Generic FDCs were available to GFATM recipients in 2004 but to PEPFAR recipients only after FDA approval in 2006. Price trends for single-component generic medicines mirrored generic FDC prices. Two large-scale purchasers, PEPFAR and UNITAID, together accounted for 53%, 84%, and 77% of market volume for abacavir, emtricitabine, and tenofovir, respectively, in 2008. PEPFAR and UNITAID purchases were often split across two manufacturers. Conclusions: Global initiatives facilitated the creation of fairly efficient markets for older ARVs, but markets for newer ARVs are less competitive and slower to evolve. WHO guidelines shape demand, and their complexity may help or hinder achievement of economies of scale in pharmaceutical manufacturing. Certification programs assure ARV quality but can delay uptake of new formulations. Large-scale procurement policies may decrease the numbers of buyers and sellers, rendering the market less competitive in the longer-term. Global policies must be developed with consideration for their short- and long-term impact on market dynamics.


Related Articles

  • HIV Testing and Treatment Among Tuberculosis Patients -- Kenya, 2006-2009. Sitienei, J.; Kipruto, H.; Nganga, L.; Ackers, M.; Odhiambo, J.; Laserson, K.; Nakashima, A. K.; Modi, S. // MMWR: Morbidity & Mortality Weekly Report;11/26/2010, Vol. 59 Issue 46, p1514 

    The article discusses a report on HIV data from Kenya's tuberculosis (TB) surveillance system from 2006 to 2009. The Kenya Division of Leprosy, Tuberculosis and Lung Disease (DLTLD) added HIV testing and treatment to its TB surveillance program at the recommendation of the World Health...

  • The Strategic Use of Antiretrovirals to Prevent HIV Infection: A Converging Agenda. Baggaley, Rachel; Doherty, Meg; Ball, Andrew; Ford, Nathan; Hirnschall, Gottfried // Clinical Infectious Diseases;2015 Supplement, Vol. 60, pS159 

    There is a clear convergence toward an overarching strategic use of antiretroviral drugs to prevent human immunodeficiency virus (HIV) infection. Four interventions-immediate antiretroviral therapy (ART) for the infected partner in a serodiscordant couple, preexposure prophylaxis (PrEP),...

  • First WHO guidance on antiretrovirals in HIV prophylaxis.  // PharmacoEconomics & Outcomes News;8/4/2012, Issue 659, p2 

    The article reports on the publication of the first guideline by the World Health Organization in August 2012 on the use of antiretrovirals in pre-exposure prophylaxis for the management of people who are at risk of HIV infection.

  • Postexposure Prophylaxis Against Human Immunodeficiency Virus (HIV): New Guidelines From the WHO: A Perspective. Kaplan, Jonathan E.; Dominguez, Kenneth; Jobarteh, Kebba; Spira, Thomas J. // Clinical Infectious Diseases;2015 Supplement, Vol. 60, pS196 

    The author comments on guidelines issued by the World Health Organization (WHO) regarding post-exposure prophylaxis against human immunodeficiency virus (HIV). Topics discussed include limited availability of evidence supporting use of post-exposure prophylaxis in prevention of HIV infection,...

  • WHO's use of generic antiretrovirals needs support.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p2 

    Presents information on a program implemented by the World Health Organization to increase access to antiretrovirals for HIV-infected individuals in developing countries. Efforts to prove the bioequivalence of generic and brand-name antiretrovirals; Criticism of various international agencies...

  • Monitoring of antiretroviral safety and efficacy.  // WHO Drug Information;2004, Vol. 18 Issue 3, p228 

    The article reports that many countries in Africa are introducing combinations of antiretrovirals as part of the World health Organization's (WHO) 3 by 5 Strategy to provide antiretroviral treatment to 3 million people by 2005. A workshop has been organized by WHO in South Africa from September...

  • Assessing the accessibility of HIV care packages among tuberculosis patients in the Northwest Region, Cameroon. Njozing, Nwarbébé Barnabas; Miguel, San Sebastian; Tih, Pius Muffih; Hurtig, Anna-Karin // BMC Public Health;2010, Vol. 10 Issue 1, p129 

    Background: Tuberculosis (TB) and human immunodeficiency virus (HIV) co-infection is a major source of morbidity and mortality globally. The World Health Organization (WHO) has recommended that HIV counselling and testing be offered routinely to TB patients in order to increase access to HIV...

  • NEW HIV RECOMMENDATIONS TO IMPROVE HEALTH, REDUCE INFECTIONS AND SAVE LIVES.  // Central European Journal of Public Health;2010, Vol. 18 Issue 2, p115 

    The article reports on HIV recommendations that will be released by the World Health Organization (WHO) in 2010. The recommendations will include the use of antiretroviral drugs (ARVs) for the reduction of HIV transmission between mother and child, the type of ARVs that will be delivered, and...

  • Adult antiretroviral therapy at a glance. Smith, Haley // South African Pharmaceutical Journal;2014, Vol. 81 Issue 9, p27 

    Dealing with the challenges of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) continues to be a major global and regional health priority. According to estimates by the World Health Organization and the Joint United Nations Programme on HIV/AIDS, 35.3-million...

  • Clinical illness as a marker for initiation of HIV antiretroviral therapy in a rural setting, Rakai, Uganda. Spacek, Lisa A.; Gray, Ronald H.; Wawer, Maria J.; Sewankambo, Nelson K.; Serwadda, David; Wabwire-Mangen, Fred; Kiwanuka, Noah; Kigozi, Godfrey; Nalugoda, Fred; Quinn, Thomas C. // International Journal of STD & AIDS;Feb2006, Vol. 17 Issue 2, p116 

    The aim of this study is to assess whether HIV-related illness and World Health Organization (WHO) clinical stage can be used to guide initiation of antiretroviral therapy (ART) in rural Rakai District, Uganda. A retrospective cohort analysis of 910 HIV-seroprevalent individuals randomly sampled...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics